C
Christian Bull
Researcher at University of Zurich
Publications - 2
Citations - 567
Christian Bull is an academic researcher from University of Zurich. The author has contributed to research in topics: Randomized controlled trial & Placebo. The author has an hindex of 2, co-authored 2 publications receiving 521 citations.
Papers
More filters
Journal ArticleDOI
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema
Marco Cicardi,Aleena Banerji,F. Bracho,Alejandro Malbrán,Bernd Rosenkranz,Marc A. Riedl,Konrad Bork,William R. Lumry,Werner Aberer,Henning Bier,Murat Bas,Jens Greve,Thomas K. Hoffmann,Henriette Farkas,Avner Reshef,Bruce Ritchie,William H. Yang,Jürgen Grabbe,Shmuel Kivity,Wolfhart Kreuz,Robyn J. Levy,Thomas A. Luger,Krystyna Obtułowicz,Peter Schmid-Grendelmeier,Christian Bull,Brigita Sitkauskiene,William B Smith,Elias Toubi,Sonja Werner,Suresh Anné,Janne Björkander,Laurence Bouillet,Enrico Cillari,D. Hurewitz,Kraig W. Jacobson,Constance H. Katelaris,Marcus Maurer,Hans F. Merk,Jonathan A. Bernstein,Conleth Feighery,Bernard Floccard,Gerald J. Gleich,Jacques Hébert,Martin Kaatz,Paul K. Keith,Charles H. Kirkpatrick,David Langton,Ludovic Martin,Christiane Pichler,David Resnick,Duane Wombolt,Diego S. Fernández Romero,Andrea Zanichelli,Francesco Arcoleo,Jochen Knolle,Irina Kravec,Liying Dong,Jens Zimmermann,Kimberly Rosen,Wing Tze Fan +59 more
TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.
Journal ArticleDOI
Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations.
Nicola L. Schoenewolf,Christian Bull,Benedetta Belloni,David Holzmann,Sabina Tonolla,Roland Lang,Daniela Mihic-Probst,Christian Andres,Reinhard Dummer +8 more
TL;DR: KIT aberrations predict the outcome of targeted therapies in acrolentiginous (ALM) and mucosal (MM) melanoma patients and especially vulvar melanomas patients should be screened for activating KIT mutations.